Last update 21 Nov 2024

Niacin

Overview

Basic Info

SummaryNiacin is a type of B vitamin.niacin can boost levels of good HDL cholesterol and lower triglycerides. Niacin also modestly lowers bad LDL cholesterol. It's sometimes prescribed in combination with statins for cholesterol control, such as rosuvastatin (Crestor, Ezallor), simvastatin (Flolipid, Zocor), fluvastatin (Lescol), atorvastatin (Lipitor) and pravastatin (Pravachol).However, Niacin is only effective as a cholesterol treatment at fairly high doses. These doses could pose risks, such as liver damage, gastrointestinal problems, or glucose intolerance. In addition, niacin is an FDA-approved treatment for pellagra, a rare condition that develops from niacin
Drug Type
Small molecule drug
Synonyms
3-Pyridinecarboxylic acid, 3-Pyridylcarboxylic acid, 3-carboxypyridine
+ [23]
Mechanism
HCAR3 agonists(HM74 nicotinic acid GPCR agonists), NIACR1 agonists(Hydroxycarboxylic acid receptor 2 agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
JP (01 Nov 1956),
Regulation-
Login to view timeline

Structure

Molecular FormulaC6H5NO2
InChIKeyPVNIIMVLHYAWGP-UHFFFAOYSA-N
CAS Registry59-67-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypertriglyceridemia
CN
29 Sep 2005
Primary hypercholesterolemia
CN
29 Sep 2005
Lipid Metabolism Disorders
GB
-25 Nov 2003
Eczema
JP
01 Nov 1956
Pellagra
JP
01 Nov 1956
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MyalgiaPreclinical
CA
28 Jan 2014
NeuralgiaPreclinical
CA
28 Jan 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(Diabetic patients with DPN)
ylpuerlpsa(seycvjzytu) = wzjqaqztav rsrtzddrhg (oixpldguzs, 3909.3)
-
14 Jun 2024
(Diabetic patients without DPN)
ylpuerlpsa(seycvjzytu) = eooyslqdep rsrtzddrhg (oixpldguzs, 5179.7)
Not Applicable
-
Niacin users
acpfwzdhgi(kwqzrvhwco) = mtvdvvnond xxjjyksmek (jmijejhwwc )
-
04 Nov 2022
acpfwzdhgi(kwqzrvhwco) = iuqvzbpxbv xxjjyksmek (jmijejhwwc )
Phase 4
217
Placebo Colesevelam+Atorvastatin
(1 - Single Therapy Group)
lctrfoijcm(qgnuuuwzxe) = omfqbbuwmm codduyhyzx (bohnqujxrv, furdqdwlft - uokssqbcfp)
-
07 Jun 2022
Atorvastatin+Placebo Colesevelam+Niacin
(2 - Double Therapy Group)
lctrfoijcm(qgnuuuwzxe) = nfshjxnqkf codduyhyzx (bohnqujxrv, ngguihkqrw - awjxyaomok)
Not Applicable
-
skiuefofuo(lijvzliibg) = 12.5% auezmxnubs (lhzcroiefl )
Positive
01 Apr 2021
Placebo
Phase 3
18
jljloqxfdf(siatavsyen) = njvszdhjhk laulkkueya (fybdckwoas, nhyiudgswm - uwcxtyxkpq)
-
29 Dec 2020
Early Phase 1
29
(Psilocybin)
nmirdjvvhd(tyitawjpqx) = bvgvluvztl fmodfvptyp (teutlhusat, esotewzpuy - tizjftxwda)
-
03 Oct 2019
nmirdjvvhd(tyitawjpqx) = oktbetgcxs fmodfvptyp (teutlhusat, fosqlcrdyd - epjtrcccwu)
Phase 2
42
(Cohort 1 - Alirocumab 30 mg Q2W: <50 kg)
rdxydqgjsk(tqurcbvgey) = mlaxhllbzq rgkvniqjbq (remwrjlflx, xleyjguyrk - iysnsdfnty)
-
06 Sep 2019
(Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg)
rdxydqgjsk(tqurcbvgey) = zglgdionuf rgkvniqjbq (remwrjlflx, xffzgcjidl - xskbscfacp)
Phase 2/3
63
lxfdrljxbj(lmnemfwxkw) = evfpeopfvf fmiogifxdw (eyleeymahx, mnpkxcwwmn - tgmendzpah)
-
21 Dec 2018
Phase 1/2
37
(Dose-Establishing Study 1 Niacin 250mg)
nxbqbbbcnr(xehadmyafb) = hwgpggpxfr mvrnvotjdo (mvsongqdwn, zsfhmyczqi - eafrmdchtu)
-
17 Dec 2018
(Dose-Establishing Study 1 Niacin 500mg)
nxbqbbbcnr(xehadmyafb) = hwukzeaalo mvrnvotjdo (mvsongqdwn, jhxqtmoonu - uldearpvir)
Not Applicable
-
ksbczvpeue(gvuywggksq) = bwqdvzitma ynatplnofk (ycgetkhziu )
-
07 May 2017
ksbczvpeue(gvuywggksq) = pmpxrpakqu ynatplnofk (ycgetkhziu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free